|
|
|
|
|
|
|
SIZE:
|
|
|
|
GENERIC NAME:
|
|
|
|
MANUFACTURER:
|
|
|
|
UNIT:
|
|
|
|
ADMINISTRATION ROUTE:
|
|
|
|
FDA PREGNANCY GROUP:
|
|
C
|
|
INDICATIONS:
|
|
Bulimia nervosa |
|
Depression |
|
Obsessive compulsive disorder |
|
Panic disorder |
|
Premenstrual dysphoric disorder |
| |
|
|
SIDE EFFECTS:
|
|
vomiting |
|
weight gain |
|
weight loss |
|
menstrual pain |
|
photosensitivity |
|
vasodilation |
|
yawning |
|
Agitation |
|
anxiety |
|
dizziness |
|
fatigue |
|
headache |
|
malaise |
|
nausea |
|
sweating |
|
vertigo |
|
Akathisia |
|
sexual dysfunction, including abnormal ejaculation |
|
anorgasmia |
|
decreased libido |
|
genital anesthesia (rare) |
|
impotence |
|
skin rash, hives, or itching |
|
Chills or fever |
|
joint or muscle pain |
|
Abnormal bleeding |
|
breast enlargement or pain |
|
dyspnea |
|
galactorrhea |
|
hypoglycemia |
|
hyponatremia |
|
mania or hypomania |
|
movement disorders |
|
palpitation |
|
seizures |
|
serotonin syndrome |
|
Anxiety or nervousness |
|
anorexia |
|
asthenia |
|
diarrhea |
|
drowsiness |
|
headache |
|
increased sweating |
|
insomnia |
|
nausea |
|
tremor |
|
Abnormal dreams |
|
alopecia |
|
changes in vision |
|
chest pain |
|
dizziness or lightheadedness |
|
frequent urination |
|
gastrointestinal effects, including change in sense of taste |
|
constipation |
|
dryness of mouth |
|
increased appetite |
|
stomach cramps, gas, or pain |
|
|
ABSOLUTE
CONTRAINDICATIONS :
|
|
|
|
RELATIVE
CONTRAINDICATIONS : |
|
Diabetes mellitus |
|
>> Hepatic function impairment |
|
Neurological impairment, including developmental delay |
|
Seizures |
|
Parkinson's disease |
|
Renal function impairment |
|
Sensitivity to fluoxetine |
|
Weight loss |
|
|
ADULT DOSE:
|
|
Antidepressant or
Antiobsessional agent or
Premenstrual dysphoric disorder -Oral, initially 20 mg (base) a day as a single morning dose .
The dose may be increased as needed and tolerated at intervals of four to eight weeks .
Note: Some clinicians begin fluoxetine therapy with a single morning dose of 5 to 10 mg (base) .
The manufacturer states that, in the treatment of depression or obsessive-compulsive disorder, doses over 20 mg (base) a day may be taken as a single morning dose or in two divided doses, in the morning and at noon .
Antibulimic agent-Oral, the target dose is 60 mg (base) a day as a single morning dose .
Patients may need to be titrated up to this dose over several days .
Note: For all indications, patients with hepatic function impairment should receive a lower dosage or less frequent dosing .
Also, for elderly patients and patients who have concurrent illness or who are taking multiple medications, a lower dosage or less frequent dosing should be considered .
For patients with renal function impairment, dosage adjustments are not routinely required . |
|
MAXIMUM ADULT DOSE:
|
|
80 mg (base) a day .
|
|
PEDIATRIC DOSE:
|
|
Safety and efficacy have not been established .
|
|
MAXIMUM PEDIATRIC
DOSE:
|
|
|
|
ELDERLY DOSE:
|
|
Antidepressant or
Antiobsessional agent or
Premenstrual dysphoric disorder -Oral, initially 20 mg (base) a day as a single morning dose .
The dose may be increased as needed and tolerated at intervals of four to eight weeks .
Note: Some clinicians begin fluoxetine therapy with a single morning dose of 5 to 10 mg (base) .
The manufacturer states that, in the treatment of depression or obsessive-compulsive disorder, doses over 20 mg (base) a day may be taken as a single morning dose or in two divided doses, in the morning and at noon .
Antibulimic agent-Oral, the target dose is 60 mg (base) a day as a single morning dose .
Patients may need to be titrated up to this dose over several days .
Note: For all indications, patients with hepatic function impairment should receive a lower dosage or less frequent dosing .
Also, for elderly patients and patients who have concurrent illness or who are taking multiple medications, a lower dosage or less frequent dosing should be considered .
For patients with renal function impairment, dosage adjustments are not routinely required . |
|
|
|
|
|